<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02089269</url>
  </required_header>
  <id_info>
    <org_study_id>iOM-01281</org_study_id>
    <secondary_id>Tumorregister Pankreaskarzinom</secondary_id>
    <nct_id>NCT02089269</nct_id>
  </id_info>
  <brief_title>Tumor Registry Pancreatic Cancer</brief_title>
  <acronym>TPK</acronym>
  <official_title>Clinical Registry on Treatment Reality and Sequential Treatments of Patients With Resectable or Locally Advanced/Metastatic Pancreatic Cancer in Real-life Practice in Germany</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iOMEDICO AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>iOMEDICO AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The registry aims to collect and analyse information on the antineoplastic treatment of
      patients with unresectable locally advanced or metastatic pancreatic cancer, treated in
      palliative intention (cohort 1) and patients with localized, resectable pancreatic cancer
      treated in neo-adjuvant or adjuvant intention (cohort 2) in daily routine practice in
      Germany. The registry will follow up patients for two years. It will identify common
      sequences of treatments used as well as changes in the treatment of the disease.
      Health-related quality of life will be analysed during the course of the treatment (PanLife).
      Based on the available data a prognostic score will be developed.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Treatment reality in Germany</measure>
    <time_frame>over 5 years</time_frame>
    <description>description of treatments selected for patients per line of therapy over the course of the project</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Pancreas Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <description>1,625 patients with unresectable locally advanced or metastatic pancreatic cancer, treated in palliative intention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <description>100 patients with localized, resectable pancreatic cancer treated in neo-adjuvant or adjuvant intention</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with pancreatic cancer undergoing antineoplastic treatment.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  resectable or locally advanced/metastatic pancreatic cancer

          -  18 years and older

          -  Antineoplastic treatment

          -  Date of consent no later than 2 weeks after start of first-line treatment

        Exclusion Criteria:

          -  No pancreatic cancer

          -  Below 18 years and older

          -  No antineoplastic treatment

          -  Date of consent later than 2 weeks after start of first-line treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susanna Hegewisch-Becker, Prof. MD</last_name>
    <role>Study Chair</role>
    <affiliation>Outpatient Clinic, Hamburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adrian Binninger</last_name>
    <phone>+4976115242-0</phone>
    <email>info@iomedico.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>iOMEDICO</name>
      <address>
        <city>Freiburg</city>
        <state>BW</state>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Hegewisch-Becker S, Aldaoud A, Wolf T, Krammer-Steiner B, Linde H, Scheiner-Sparna R, Hamm D, JÃ¤nicke M, Marschner N; TPK-Group (Tumour Registry Pancreatic Cancer). Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma. Int J Cancer. 2019 Mar 1;144(5):981-990. doi: 10.1002/ijc.31751. Epub 2018 Oct 3.</citation>
    <PMID>30006989</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 14, 2014</study_first_submitted>
  <study_first_submitted_qc>March 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2014</study_first_posted>
  <last_update_submitted>February 27, 2020</last_update_submitted>
  <last_update_submitted_qc>February 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pancreatic neoplasms</keyword>
  <keyword>neoplasms</keyword>
  <keyword>registry</keyword>
  <keyword>advanced pancreatic cancer</keyword>
  <keyword>health services research</keyword>
  <keyword>epidemiology</keyword>
  <keyword>Germany</keyword>
  <keyword>palliative treatment</keyword>
  <keyword>palliative care</keyword>
  <keyword>localized, resectable pancreatic cancer</keyword>
  <keyword>adjuvant treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

